Adding Infliximab to the Treatment Regimen for Giant Cell Arteritis. Ann Intern Med. 2007;146:I-12. doi: 10.7326/0003-4819-146-9-200705010-00001
Download citation file:
Published: Ann Intern Med. 2007;146(9):I-12.
Giant cell arteritis (GCA, also called temporal arteritis) involves inflammation of large and medium-sized arteries (vasculitis). This condition occurs in elderly people and can lead to sudden blindness. Prompt treatment can prevent blindness. Standard therapy for GCA consists of large doses of steroid drugs (such as prednisone), followed by a gradual decrease in the dose. Patients may need to take a low dose of steroid for many years. Unfortunately, in many patients, symptoms (including muscle ache, fatigue, headache, and change in vision) return as the dose is lowered, or side effects from the steroid develop. Thus, we need better ways to treat GCA. Infliximab is a drug that blocks an inflammatory chemical (called tumor necrosis factor, or TNF) of the immune system. There is evidence that TNF plays a role in GCA. Earlier reports in small numbers of patients have suggested that blocking the effects of TNF may decrease the amount of steroid needed to treat GCA.
To find out whether treatment with infliximab improved outcomes for people with GCA.
44 patients with newly diagnosed GCA who had responded to steroid treatment.
The researchers assigned patients at random to receive an intravenous dose of either infliximab or a placebo (a substance that looked like infliximab but contained no active ingredient) at the start of the study; after 2, 6, and 8 weeks; and then every 8 weeks after that. All patients followed a schedule to slowly decrease the steroid dose. If symptoms returned, patients would need to increase the steroid dose and start to decrease the amount they received all over again. The researchers collected information on whether patients' symptoms returned (called relapse) and on steroid dose over the course of the study. The researchers planned for the study to last 54 weeks.
Although the study was supposed to continue for 54 weeks, the researchers stopped it after 22 weeks because infliximab did not appear to benefit patients in terms of preventing relapse of symptoms or reducing the amount of steroids required for treatment.
The study was small and stopped early, so the researchers could not rule out a small benefit of infliximab. The study was also too small and brief to provide extensive information on the side effects of infliximab.
Infliximab is unlikely to benefit patients with newly diagnosed GCA.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Neurology, Rheumatology, Vasculitides, Giant Cell Arteritis/Polymyalgia Rheumatica.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only